Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.

@article{Mantha2017DeterminantsOF,
  title={Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.},
  author={Simon Mantha and Debra A. Goldman and Sean M. Devlin and Ju-Whei Lee and Diana Zannino and Marnie Collins and Dan Douer and Harry J Iland and Mark R. Litzow and Eytan M. Stein and Frederick R. Appelbaum and Richard A. Larson and Richard M. Stone and Bayard L. Powell and Susan Michelle Geyer and Kristina M Laumann and Jacob M. Rowe and Harry P. Erba and Steven Coutre and Megan Othus and Jae H. Park and Peter H Wiernik and Martin S. Tallman},
  journal={Blood},
  year={2017},
  volume={129 13},
  pages={
          1763-1767
        }
}
Acute promyelocytic leukemia (APL) is commonly complicated by a complex coagulopathy. Uncertainty remains as to which markers of bleeding risk are independent predictors. Drawing from 5 large clinical trials that included all-trans retinoic acid (ATRA) as part of induction, we assessed known determinants of bleeding at baseline and evaluated them as potential predictors of hemorrhagic death (HD) in the first 30 days of treatment. The studies included were ALLG APML3 (single arm of ATRA… 
Retrospective analysis of data from 73 patients with childhood acute promyelocytic leukaemia receiving modified chemotherapy: a single-centre study
TLDR
Idarubicin for hyperleukocytosis control in induction therapy is safe and effective for paediatric APL and risk-adapted attenuated consolidation chemotherapy is advocated.
Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study
TLDR
When the survival of APL patients normalizes to that of a gender, age, and calendar-yearmatched general population is investigated to restore normal coagulation and reduce risk of early deaths.
The evaluation of risk factors leading to early deaths in patients with acute promyelocytic leukemia: a retrospective study
TLDR
Factors associated with ED and applicability of scoring systems used to diagnose DIC are evaluated and common utilization of ATRA and arsenic trioxide (ATO) may be beneficial to overcome ED and coagulopathy in APL patients.
Drug treatment options for acute promyelocytic leukemia
TLDR
The story of APL represents a pioneering model for the development of precision medicine and curative chemotherapy-free approaches for acute leukemia and new therapeutic landscapes contemplate the use of an oral chemo-free ATRA-ATO combination, implementing treatment as outpatient care, thus increasing quality of life and decreasing medical costs.
Acute Promyelocytic Leukemia: A History over 60 Years—From the Most Malignant to the most Curable Form of Acute Leukemia
TLDR
The six-decade history of APL is reviewed, from its initial characterization to the era of chemotherapy-free ATRA-ATO, a model of cancer-targeted therapy, which is currently the most curable form of AML in adults.
Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide
TLDR
A high rate of ED is revealed, and the causes of ED were similar to those among patients who received ATRA-based therapy, and increased creatinine level was the most powerful predictor.
...
...

References

SHOWING 1-10 OF 57 REFERENCES
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.
TLDR
Clinical relevant information is furnished that might be useful for designing more appropriately risk-adapted treatment protocols aimed at reducing the considerable problem of induction mortality in APL.
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.
TLDR
The lower dose of mitoxantrone resulted in a significant reduction of toxicity and hospital stay while maintaining the antileukemic activity, and the combination of ATRA, idarubicin, and cytarabine for high-risk acute promyelocytic leukemia significantly reduced the relapse rate in this setting.
Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group.
  • N. Asou, K. Adachi, R. Ohno
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
TLDR
The results show that age, hemorrhagic diathesis, and initial leukocyte count are prognostic factors for APL treated with ATRA followed by intensive chemotherapy.
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.
TLDR
Long-term follow-up of the North American Intergroup APL trial reported a benefit for all-trans retinoic acid (ATRA) in both induction and maintenance therapy in patients with acute promyelocytic leukemia (APL), and female sex, classical M3 morphology, and treatment-white blood cell count (WBC) interaction were each significantly associated with improved DFS.
AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance.
All-trans-retinoic acid (ATRA) has greatly modified the prognosis of acute promyelocytic leukemia; however, the role of maintenance in patients in molecular complete remission after consolidation
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.
TLDR
The 10-year cumulative incidence of deaths in complete response (CR) was 5.7%, 15.4%, and 21.7% in patients younger than 55, 55 to 65, and older than 65 years, respectively, supporting the need for less myelosuppressive treatments, particularly for consolidation therapy.
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
TLDR
The addition of As(2)O(3) consolidation to standard induction and consolidation therapy significantly improves event-free and disease-free survival in adults with newly diagnosed APL.
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
TLDR
ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL.
...
...